General Committee of Teaching Hospitals and Institutes, Egypt Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2014
NCT02138331
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

General Committee of Teaching Hospitals and Institutes, Egypt

Active Ingredients

Drugs in Phase 3 Trials (2)

magnesium sulfate (Tis-U-Sol) (1 trial)

msc (1 trial)

Drugs in Other Trials (1)

liraglutide (victoza) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Hemorrhage (Phase 3)

Subarachnoid Hemorrhage (Phase 3)

Vasospasm, Intracranial (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3